Annexin A2 in renal cell carcinoma: expression, function, and prognostic significance.

OBJECTIVE Renal cell carcinoma (RCC) is the most lethal genitourinary cancer and intrinsically resistant to chemotherapy, radiotherapy, and hormone therapy. Annexin A2 (Anxa2) is a calcium-dependent phospholipid-binding protein found on various cell types that plays multiple roles in regulating cellular functions. In RCC, Anxa2 expression was correlated with tumor differentiation, clinical outcomes, and the metastatic potential; however, the underlying mechanisms remain obscure. This study investigated the role of Anxa2 in regulating tumorigenesis of RCC. MATERIALS AND METHODS Commercial RCC tissue microarray arrays and a kidney cancer quantitative polymerase chain reaction array were used to examine Anxa2 by immunohistochemistry and real-time polymerase chain reaction analysis. Short hairpin (sh)RNA-based lentiviral system technology was used to evaluate the effects of manipulating Anxa2 expression on multiple malignant features of 2 RCC cell lines, A498 and 786-O, and its mechanisms. RESULTS (1) The Anxa2 expression level was generally elevated to varying degrees in RCC tissues. In adjacent noncancerous tissues, Anxa2 was mainly expressed in glomeruli and slightly expressed in the cytoplasm of proximal tubules. (2) An increased Anxa2 expression level was found in tissues of clear cell RCC, papillary RCC, and chromophobe RCC, and it was prominently expressed in cancer cell membranes. In addition, the Anxa2 expression level was correlated with poor prognosis. (3) Silencing Anxa2 expression suppressed the abilities of cell migration and invasion, but cell proliferation was less affected. (4) Diminished Anxa2 expression caused alterations in the cell polarity, disrupted the formation of actin filaments, and reduced CXCR4 expression. (5) Inhibition of the Rho/Rock axis restored silencing of Anxa2-mediated suppression of cell motility. CONCLUSIONS Overall, our study points out the regulatory function of Anxa2 in RCC cell motility and provides a molecular-based mechanism of Anxa2 positivity in the progression of RCC.

[1]  D. Waisman,et al.  Annexin A2 Heterotetramer: Structure and Function , 2013, International journal of molecular sciences.

[2]  Y. Kanai,et al.  Genetic and epigenetic alterations during renal carcinogenesis. , 2011, International journal of clinical and experimental pathology.

[3]  J. Vishwanatha,et al.  Annexin II expression is regulated during mammalian cell cycle. , 1993, Cancer research.

[4]  Judong Pan,et al.  Stromal Derived Factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis , 2006, Molecular Cancer.

[5]  C. Charbonneau,et al.  Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.

[6]  E. Babiychuk,et al.  Annexins in Cell Membrane Dynamics , 2000, The Journal of cell biology.

[7]  M. Tachibana,et al.  Annexin II represents metastatic potential in clear-cell renal cell carcinoma , 2009, British Journal of Cancer.

[8]  S. Moss,et al.  Annexins: linking Ca2+ signalling to membrane dynamics , 2005, Nature Reviews Molecular Cell Biology.

[9]  Ya‐Wen Cheng,et al.  MicroRNA-224 Suppresses Colorectal Cancer Cell Migration by Targeting Cdc42 , 2014, Disease markers.

[10]  D. Skarecky,et al.  Annexin A2 positively contributes to the malignant phenotype and secretion of IL‐6 in DU145 prostate cancer cells , 2009, International journal of cancer.

[11]  Ann Chen,et al.  Nephronectin expression in nephrotoxic acute tubular necrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  Yi-Ting Fang,et al.  Annexin A2 Silencing Induces G2 Arrest of Non-small Cell Lung Cancer Cells through p53-dependent and -independent Mechanisms* , 2012, The Journal of Biological Chemistry.

[13]  Wei-Hwa Lee,et al.  Calcium-binding proteins annexin A2 and S100A6 are sensors of tubular injury and recovery in acute renal failure. , 2005, Kidney international.

[14]  K. Shroyer,et al.  Annexin A2 Promotes Glioma Cell Invasion and Tumor Progression , 2011, The Journal of Neuroscience.

[15]  A. Maitra,et al.  Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer , 2011, PloS one.

[16]  P. Galle,et al.  Strong Expression of Chemokine Receptor CXCR4 by Renal Cell Carcinoma Correlates with Advanced Disease , 2008, Journal of oncology.

[17]  H. Moch,et al.  Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.

[18]  Zhiyong Zhang,et al.  Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis , 2010, Journal of cellular biochemistry.

[19]  Y. Shiozawa,et al.  Annexin-2 is a regulator of stromal cell-derived factor-1/CXCL12 function in the hematopoietic stem cell endosteal niche. , 2011, Experimental hematology.

[20]  C. Ricciardelli,et al.  The Role of Annexin A2 in Tumorigenesis and Cancer Progression , 2011, Cancer Microenvironment.

[21]  Asma Nusrat,et al.  Annexin 2 regulates intestinal epithelial cell spreading and wound closure through Rho-related signaling. , 2007, The American journal of pathology.

[22]  U. Rescher,et al.  Tyrosine phosphorylation of annexin A2 regulates Rho-mediated actin rearrangement and cell adhesion , 2008, Journal of Cell Science.

[23]  A. Hall,et al.  Cell migration: Rho GTPases lead the way. , 2004, Developmental biology.

[24]  Wei Wu,et al.  Inhibition of Annexin A2 gene transcription is a promising molecular target for hepatoma cell proliferation and metastasis , 2013, Oncology letters.

[25]  P. Hoffmann,et al.  Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis , 2013, Oncotarget.

[26]  D. Schols,et al.  CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. , 2010, Current pharmaceutical design.

[27]  M. Menon,et al.  The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. , 2014, Urologic oncology.

[28]  Zhengwei Yang,et al.  Overexpression of Annexin A2 Is Associated with Abnormal Ubiquitination in Breast Cancer , 2012, Genom. Proteom. Bioinform..

[29]  W. Paulus,et al.  Knockdown of annexin 2 decreases migration of human glioma cells in vitro , 2006, Neuropathology and applied neurobiology.

[30]  T. Teratani,et al.  Evaluation of S100A10, annexin II and B‐FABP expression as markers for renal cell carcinoma , 2007, Cancer science.

[31]  J. Ruan,et al.  Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma , 2009, International journal of hematology.

[32]  S. Moss,et al.  Annexins: from structure to function. , 2002, Physiological reviews.

[33]  S. Pietschmann,et al.  Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome , 2004, Virchows Archiv.

[34]  Chun-Chao Chang,et al.  Silencing glucose-regulated protein 78 induced renal cell carcinoma cell line G1 cell-cycle arrest and resistance to conventional chemotherapy. , 2014, Urologic oncology.

[35]  A. Rizzino,et al.  Specific down-regulation of annexin II expression in human cells interferes with cell proliferation , 1999, Molecular and Cellular Biochemistry.